Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma

Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant...

Full description

Saved in:

Bibliographic Details
Published in:	Neural regeneration research Vol. 18; no. 4; pp. 840 - 848
Main Authors:	Basavarajappa, Devaraj, Gupta, Vivek, Chitranshi, Nitin, Wall, Roshana, Rajput, Rashi, Pushpitha, Kanishka, Sharma, Samridhi, Mirzaei, Mehdi, Klistorner, Alexander, Graham, Stuart
Format:	Journal Article
Language:	English
Published:	Mumbai Wolters Kluwer India Pvt. Ltd 01.04.2023 Medknow Publications & Media Pvt. Ltd Department of Clinical Medicine,Faculty of Medicine,Health and Human Sciences,Macquarie University,North Ryde,Sydney,NSW,Australia Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications
Subjects:	Glaucoma glaucoma; intraocular pressure; neurodegeneration; neuroprotection; optic nerve injury; retinal ganglion cells; siponimod; sphingosine-1-phosphate Nervous system Optic nerve Retina intraocular pressure glaucoma neuroprotection neurodegeneration optic nerve injury retinal ganglion cells sphingosine-1-phosphate siponimod
ISSN:	1673-5374, 1876-7958
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant drug for managing secondary progressive multiple sclerosis. We investigated its neuroprotective properties in vivo on the retina and the brain in an optic nerve injury model induced by a chronic increase in intraocular pressure or acute N-methyl-D-aspartate excitotoxicity. Neuronal-specific deletion of sphingosine-1-phosphate receptor (S1PR1) was carried out by expressing AAV-PHP.eB-Cre recombinase under Syn1 promoter in S1PR1flox/flox mice to define the role of S1PR1 in neurons. Inner retinal electrophysiological responses, along with histological and immunofluorescence analysis of the retina and optic nerve tissues, indicated significant neuroprotective effects of siponimod when administered orally via diet in chronic and acute optic nerve injury models. Further, siponimod treatment showed significant protection against trans-neuronal degenerative changes in the higher visual center of the brain induced by optic nerve injury. Siponimod treatment also reduced microglial activation and reactive gliosis along the visual pathway. Our results showed that siponimod markedly upregulated neuroprotective Akt and Erk1/2 activation in the retina and the brain. Neuronal-specific deletion of S1PR1 enhanced retinal and dorsolateral geniculate nucleus degenerative changes in a chronic optic nerve injury condition and attenuated protective effects of siponimod. In summary, our data demonstrated that S1PR1 signaling plays a vital role in the retinal ganglion cell and dorsolateral geniculate nucleus neuronal survival in experimental glaucoma, and siponimod exerts direct neuroprotective effects through S1PR1 in neurons in the central nervous system independent of its peripheral immuno-modulatory effects. Our findings suggest that neuronal S1PR1 is a neuroprotective therapeutic target and its modulation by siponimod has positive implications in glaucoma conditions.
AbstractList	Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant drug for managing secondary progressive multiple sclerosis. We investigated its neuroprotective properties in vivo on the retina and the brain in an optic nerve injury model induced by a chronic increase in intraocular pressure or acute N-methyl-D-aspartate excitotoxicity. Neuronal-specific deletion of sphingosine-1-phosphate receptor (S1PR1) was carried out by expressing AAV-PHP.eB-Cre recombinase under Syn1 promoter in S1PR1flox/flox mice to define the role of S1PR1 in neurons. Inner retinal electrophysiological responses, along with histological and immunofluorescence analysis of the retina and optic nerve tissues, indicated significant neuroprotective effects of siponimod when administered orally via diet in chronic and acute optic nerve injury models. Further, siponimod treatment showed significant protection against trans-neuronal degenerative changes in the higher visual center of the brain induced by optic nerve injury. Siponimod treatment also reduced microglial activation and reactive gliosis along the visual pathway. Our results showed that siponimod markedly upregulated neuroprotective Akt and Erk1/2 activation in the retina and the brain. Neuronal-specific deletion of S1PR1 enhanced retinal and dorsolateral geniculate nucleus degenerative changes in a chronic optic nerve injury condition and attenuated protective effects of siponimod. In summary, our data demonstrated that S1PR1 signaling plays a vital role in the retinal ganglion cell and dorsolateral geniculate nucleus neuronal survival in experimental glaucoma, and siponimod exerts direct neuroprotective effects through S1PR1 in neurons in the central nervous system independent of its peripheral immuno-modulatory effects. Our findings suggest that neuronal S1PR1 is a neuroprotective therapeutic target and its modulation by siponimod has positive implications in glaucoma conditions. Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant drug for managing secondary progressive multiple sclerosis. We investigated its neuroprotective properties in vivo on the retina and the brain in an optic nerve injury model induced by a chronic increase in intraocular pressure or acute N-methyl-D-aspartate excitotoxicity. Neuronal-specific deletion of sphingosine-1-phosphate receptor (S1PR1) was carried out by expressing AAV-PHP.eB-Cre recombinase under Syn1 promoter in S1PR1flox/flox mice to define the role of S1PR1 in neurons. Inner retinal electrophysiological responses, along with histological and immunofluorescence analysis of the retina and optic nerve tissues, indicated significant neuroprotective effects of siponimod when administered orally via diet in chronic and acute optic nerve injury models. Further, siponimod treatment showed significant protection against trans-neuronal degenerative changes in the higher visual center of the brain induced by optic nerve injury. Siponimod treatment also reduced microglial activation and reactive gliosis along the visual pathway. Our results showed that siponimod markedly upregulated neuroprotective Akt and Erk1/2 activation in the retina and the brain. Neuronal-specific deletion of S1PR1 enhanced retinal and dorsolateral geniculate nucleus degenerative changes in a chronic optic nerve injury condition and attenuated protective effects of siponimod. In summary, our data demonstrated that S1PR1 signaling plays a vital role in the retinal ganglion cell and dorsolateral geniculate nucleus neuronal survival in experimental glaucoma, and siponimod exerts direct neuroprotective effects through S1PR1 in neurons in the central nervous system independent of its peripheral immuno-modulatory effects. Our findings suggest that neuronal S1PR1 is a neuroprotective therapeutic target and its modulation by siponimod has positive implications in glaucoma conditions.Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in neurodegenerative conditions is still largely unidentified. Siponimod is a specific modulator of S1P1 and S1P5 receptors, an immunosuppressant drug for managing secondary progressive multiple sclerosis. We investigated its neuroprotective properties in vivo on the retina and the brain in an optic nerve injury model induced by a chronic increase in intraocular pressure or acute N-methyl-D-aspartate excitotoxicity. Neuronal-specific deletion of sphingosine-1-phosphate receptor (S1PR1) was carried out by expressing AAV-PHP.eB-Cre recombinase under Syn1 promoter in S1PR1flox/flox mice to define the role of S1PR1 in neurons. Inner retinal electrophysiological responses, along with histological and immunofluorescence analysis of the retina and optic nerve tissues, indicated significant neuroprotective effects of siponimod when administered orally via diet in chronic and acute optic nerve injury models. Further, siponimod treatment showed significant protection against trans-neuronal degenerative changes in the higher visual center of the brain induced by optic nerve injury. Siponimod treatment also reduced microglial activation and reactive gliosis along the visual pathway. Our results showed that siponimod markedly upregulated neuroprotective Akt and Erk1/2 activation in the retina and the brain. Neuronal-specific deletion of S1PR1 enhanced retinal and dorsolateral geniculate nucleus degenerative changes in a chronic optic nerve injury condition and attenuated protective effects of siponimod. In summary, our data demonstrated that S1PR1 signaling plays a vital role in the retinal ganglion cell and dorsolateral geniculate nucleus neuronal survival in experimental glaucoma, and siponimod exerts direct neuroprotective effects through S1PR1 in neurons in the central nervous system independent of its peripheral immuno-modulatory effects. Our findings suggest that neuronal S1PR1 is a neuroprotective therapeutic target and its modulation by siponimod has positive implications in glaucoma conditions.
Author	Wall, Roshana Graham, Stuart Pushpitha, Kanishka Sharma, Samridhi Rajput, Rashi Mirzaei, Mehdi Chitranshi, Nitin Basavarajappa, Devaraj Klistorner, Alexander Gupta, Vivek
AuthorAffiliation	Department of Clinical Medicine,Faculty of Medicine,Health and Human Sciences,Macquarie University,North Ryde,Sydney,NSW,Australia
AuthorAffiliation_xml	– name: Department of Clinical Medicine,Faculty of Medicine,Health and Human Sciences,Macquarie University,North Ryde,Sydney,NSW,Australia – name: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW, Australia
Author_xml	– sequence: 1 givenname: Devaraj surname: Basavarajappa fullname: Basavarajappa, Devaraj organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 2 givenname: Vivek surname: Gupta fullname: Gupta, Vivek organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 3 givenname: Nitin surname: Chitranshi fullname: Chitranshi, Nitin organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 4 givenname: Roshana surname: Wall fullname: Wall, Roshana organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 5 givenname: Rashi surname: Rajput fullname: Rajput, Rashi organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 6 givenname: Kanishka surname: Pushpitha fullname: Pushpitha, Kanishka organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 7 givenname: Samridhi surname: Sharma fullname: Sharma, Samridhi organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 8 givenname: Mehdi surname: Mirzaei fullname: Mirzaei, Mehdi organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 9 givenname: Alexander surname: Klistorner fullname: Klistorner, Alexander organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW – sequence: 10 givenname: Stuart surname: Graham fullname: Graham, Stuart organization: Department of Clinical Medicine, Faculty of Medicine, Health and Human Sciences, Macquarie University, North Ryde, Sydney, NSW
BookMark	eNp9UktvEzEQXqEi-oA7x5W4IKEUv9e-IEHFo1IlEIWzNfHObpxu7GDvJrQnfjoOaRHtgZNHM9_3zcPfcXUQYsCqek7JqaCEv6aq4TPJG3HKhTCSPaqOqG7UrDFSH5T4rnxYHee8JERqw_iT6pArRoSW7Kj6denXMfhVbGv8iWnMdcApxXWKI7rRb7DGritRrmOoxwXWCUcfoIbQ1gvfLzDVG58nGOo1jIstXBdQilO_2OuEUrikX77S2ofSYI3JrzCMJdsPMLm4gqfV4w6GjM9u35Pq-4f3384-zS4-fzw_e3sxc1KxOGOgCW2N7JBRUPPGABCiRWccaQ0wqZQQSrVSCs4QqFNmDp02rXPQoHSUn1Tne902wtKuyxyQrm0Eb_8kYuotpNG7AS0SzbSWnBjeimauTAOddIxr2ZHOUVe03uy11tN8ha0rGyUY7onerwS_sH3cWNMQUv6tCLzaC2whdBB6u4xTKrfK9qbPy5t8vbTICONEEKYL-uVtuxR_TJhHu_LZ4TBAwDhlyxrGqTRSyAJ98QD6V7mgSKO0EqSg1B7lUsw5YWedH2H0cTetHywldmcvu_OP3fnH7u1ViOQB8W7n_1De3a4ahxFTvhqmLSZbjnMV4vYeb_YPz2pB7J03-W8KcOku
CitedBy_id	crossref_primary_10_1186_s40478_024_01804_0 crossref_primary_10_1007_s12035_023_03535_0 crossref_primary_10_1016_j_neubiorev_2024_105767 crossref_primary_10_1167_iovs_65_13_50 crossref_primary_10_1096_fj_202201346R crossref_primary_10_1096_fj_202402642R crossref_primary_10_1093_pnasnexus_pgae299 crossref_primary_10_17116_jnevro20231230728 crossref_primary_10_3390_ijms25010261 crossref_primary_10_1016_j_visres_2024_108434 crossref_primary_10_4103_NRR_NRR_D_23_01301 crossref_primary_10_7554_eLife_102151_4 crossref_primary_10_1016_j_mam_2023_101216 crossref_primary_10_7554_eLife_102151
Cites_doi	10.1161/STROKEAHA.117.018505 10.15252/emmm.201910291 10.1007/s40263-015-0297-0 10.1038/nrneurol.2012.227 10.2147/DDDT.S122249 10.1093/brain/awy338 10.1167/iovs.10-5392 10.1002/jcb.29822 10.3390/cells10113217 10.3390/cells9051108 10.1016/S0140-6736(17)31469-1 10.1007/s00401-011-0807-1 10.3389/fimmu.2020.00635 10.3390/cells9061515 10.4161/jkst.22925 10.1016/S0079-6123(08)01132-1 10.1016/j.neurobiolaging.2017.02.004 10.1038/nmeth.2089 10.1007/s11910-021-01110-5 10.1155/2016/8072156 10.1167/iovs.13-13262 10.1111/jnc.13701 10.1007/978-3-319-05879-5_7 10.3389/fneur.2020.612422 10.3389/fneur.2021.654850 10.1016/j.preteyeres.2019.100799 10.1002/glia.20962 10.1167/iovs.11-8732 10.1161/STROKEAHA.109.568899 10.3390/cells9030535 10.3390/pharmaceutics13010108 10.1186/s13578-020-00416-0 10.1016/j.neuron.2018.01.021 10.3390/cells8010024 10.1016/j.phrs.2016.07.042 10.2174/1389450116666151001112710 10.3390/molecules22030344 10.1073/pnas.1615413114 10.1016/j.neuron.2009.11.021 10.1007/s12035-020-01948-9 10.1016/j.jneuroim.2012.12.005 10.1007/s12640-019-0003-y 10.1167/iovs.02-0398 10.3390/ijms21207537 10.1016/j.brainresbull.2020.08.013 10.1001/archneur.62.9.1345 10.3389/fnmol.2018.00293 10.7150/thno.55472 10.1146/annurev-pharmtox-010818-021358 10.1016/j.exer.2011.09.023 10.1016/j.exer.2006.09.013 10.1073/pnas.1014154108 10.1016/j.neuropharm.2016.11.006 10.1080/14656566.2018.1551363 10.1056/NEJMoa052643 10.3390/cells9081771 10.1038/nn.4593 10.1515/revneuro-2013-0003 10.1093/hmg/ddv218 10.1016/j.expneurol.2019.01.015 10.1016/S0140-6736(18)30475-6 10.1096/fj.201600751r 10.1177/20552173211049168 10.1126/science.aar5551 10.1016/j.ymthe.2018.09.019 10.1016/j.bbamem.2017.03.008 10.1523/JNEUROSCI.2801-06.2006 10.1038/ncomms5859 10.1038/s41433-020-0809-0 10.1128/MCB.25.24.11113-11121.2005 10.1016/j.neuropharm.2018.02.023 10.1016/j.pneurobio.2020.101817
ContentType	Journal Article
Copyright	2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Wanfang Data Co. Ltd. All Rights Reserved. Copyright: © Neural Regeneration Research 2023
Copyright_xml	– notice: 2023. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: Copyright: © Neural Regeneration Research 2023
DBID	AAYXX CITATION K9. 7X8 2B. 4A8 92I 93N PSX TCJ 5PM DOA
DOI	10.4103/1673-5374.344952
DatabaseName	CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology
EISSN	1876-7958
EndPage	848
ExternalDocumentID	oai_doaj_org_article_e0828853093d47b697af5c2385f0fc1c PMC9700103 zgsjzsyj_e202304028 10_4103_1673_5374_344952 10.4103/1673-5374.344952_840_Siponimo
GroupedDBID	--- -SE -S~ 0R~ 53G 5RS 5VR 5VS 7X7 8FI 92F 92I ACGFS ADBBV ADJBI AENEX AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AZQEC BAWUL BENPR CAJEE CCEZO CHBEP CIEJG CS3 CW9 DIK DU5 EMOBN FA0 FDB GROUPED_DOAJ GX1 IAO IEA IHR KQ8 M2M M48 M5~ NQ- O9- OK1 OVD PGMZT PIMPY Q-- RMW RPM TCJ TEORI TGQ U1G U5O W3E WFFXF --K 123 1B1 4.4 8FJ AAEDT AAKAS AALRI AAXUO AAYXX ABUWG ABWVN ACRPL ADMUD ADNMO ADRAZ ADZCM AFFHD AFUIB CCPQU CITATION DWQXO EBS EJD EO8 FYUFA GNUQQ H13 HMCUK HYE HZ~ IHE IPNFZ ITC M41 PHGZM PHGZT PSYQQ RIG ROL RPZ UKHRP K9. 7X8 2B. 4A8 93N PMFND PSX 5PM
ID	FETCH-LOGICAL-c562o-2a801d95fe21a6b79aa0084f9c0d9a25664466d55432ea1c69baf89dcca7e5c13
IEDL.DBID	W3E
ISICitedReferencesCount	16
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000903723200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1673-5374
IngestDate	Fri Oct 03 12:43:25 EDT 2025 Tue Sep 30 17:18:22 EDT 2025 Thu May 29 04:00:49 EDT 2025 Thu Sep 04 18:21:25 EDT 2025 Tue Oct 07 07:34:11 EDT 2025 Tue Nov 18 22:51:18 EST 2025 Sat Nov 29 05:11:59 EST 2025 Tue Jun 17 22:47:45 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	4
Keywords	intraocular pressure glaucoma neuroprotection neurodegeneration optic nerve injury retinal ganglion cells sphingosine-1-phosphate siponimod
Language	English
License	http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c562o-2a801d95fe21a6b79aa0084f9c0d9a25664466d55432ea1c69baf89dcca7e5c13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Author contributions: DB, VG, MM, AK and SLG designed the study; DB, RVW, NC, KP, and RR performed the experiments; DB, VG, and SLG analyzed the data; DB and VG wrote the manuscript; MM, SS helped to write the manuscript. All authors helped to write the manuscript preparation and approved the final version of the manuscript.
ORCID	0000-0002-0202-7843 0000-0003-0997-0196
OpenAccessLink	http://www.nrronline.org/article.asp?issn=1673-5374;year=2023;volume=18;issue=4;spage=840;epage=848;aulast=Basavarajappa;type=0
PMID	36204852
PQID	2720768640
PQPubID	4671210
PageCount	9
ParticipantIDs	doaj_primary_oai_doaj_org_article_e0828853093d47b697af5c2385f0fc1c pubmedcentral_primary_oai_pubmedcentral_nih_gov_9700103 wanfang_journals_zgsjzsyj_e202304028 proquest_miscellaneous_2723159545 proquest_journals_2720768640 crossref_citationtrail_10_4103_1673_5374_344952 crossref_primary_10_4103_1673_5374_344952 wolterskluwer_medknow_10_4103_1673-5374_344952_840_Siponimo
PublicationCentury	2000
PublicationDate	20230401
PublicationDateYYYYMMDD	2023-04-01
PublicationDate_xml	– month: 4 year: 2023 text: 20230401 day: 01
PublicationDecade	2020
PublicationPlace	Mumbai
PublicationPlace_xml	– name: Mumbai – name: India
PublicationTitle	Neural regeneration research
PublicationTitle_FL	Neural Regeneration Research
PublicationYear	2023
Publisher	Wolters Kluwer India Pvt. Ltd Medknow Publications & Media Pvt. Ltd Department of Clinical Medicine,Faculty of Medicine,Health and Human Sciences,Macquarie University,North Ryde,Sydney,NSW,Australia Wolters Kluwer - Medknow Wolters Kluwer Medknow Publications
Publisher_xml	– name: Wolters Kluwer India Pvt. Ltd – name: Medknow Publications & Media Pvt. Ltd – name: Department of Clinical Medicine,Faculty of Medicine,Health and Human Sciences,Macquarie University,North Ryde,Sydney,NSW,Australia – name: Wolters Kluwer - Medknow – name: Wolters Kluwer Medknow Publications
References	key-10.4103/1673-5374.344952-73 key-10.4103/1673-5374.344952-72 key-10.4103/1673-5374.344952-31 key-10.4103/1673-5374.344952-30 key-10.4103/1673-5374.344952-33 key-10.4103/1673-5374.344952-32 key-10.4103/1673-5374.344952-35 key-10.4103/1673-5374.344952-34 key-10.4103/1673-5374.344952-8 key-10.4103/1673-5374.344952-37 key-10.4103/1673-5374.344952-7 key-10.4103/1673-5374.344952-36 key-10.4103/1673-5374.344952-6 key-10.4103/1673-5374.344952-39 key-10.4103/1673-5374.344952-5 key-10.4103/1673-5374.344952-38 key-10.4103/1673-5374.344952-9 key-10.4103/1673-5374.344952-71 key-10.4103/1673-5374.344952-70 key-10.4103/1673-5374.344952-62 key-10.4103/1673-5374.344952-61 key-10.4103/1673-5374.344952-20 key-10.4103/1673-5374.344952-64 key-10.4103/1673-5374.344952-63 key-10.4103/1673-5374.344952-22 key-10.4103/1673-5374.344952-66 key-10.4103/1673-5374.344952-21 key-10.4103/1673-5374.344952-65 key-10.4103/1673-5374.344952-24 key-10.4103/1673-5374.344952-68 key-10.4103/1673-5374.344952-23 key-10.4103/1673-5374.344952-67 key-10.4103/1673-5374.344952-26 key-10.4103/1673-5374.344952-25 key-10.4103/1673-5374.344952-69 key-10.4103/1673-5374.344952-28 key-10.4103/1673-5374.344952-27 key-10.4103/1673-5374.344952-29 key-10.4103/1673-5374.344952-60 key-10.4103/1673-5374.344952-51 key-10.4103/1673-5374.344952-50 key-10.4103/1673-5374.344952-53 key-10.4103/1673-5374.344952-52 key-10.4103/1673-5374.344952-11 key-10.4103/1673-5374.344952-55 key-10.4103/1673-5374.344952-10 key-10.4103/1673-5374.344952-54 key-10.4103/1673-5374.344952-13 key-10.4103/1673-5374.344952-57 key-10.4103/1673-5374.344952-12 key-10.4103/1673-5374.344952-56 key-10.4103/1673-5374.344952-15 key-10.4103/1673-5374.344952-59 key-10.4103/1673-5374.344952-14 key-10.4103/1673-5374.344952-58 key-10.4103/1673-5374.344952-17 key-10.4103/1673-5374.344952-16 key-10.4103/1673-5374.344952-19 key-10.4103/1673-5374.344952-18 key-10.4103/1673-5374.344952-40 key-10.4103/1673-5374.344952-42 key-10.4103/1673-5374.344952-41 key-10.4103/1673-5374.344952-44 key-10.4103/1673-5374.344952-43 key-10.4103/1673-5374.344952-46 key-10.4103/1673-5374.344952-45 key-10.4103/1673-5374.344952-48 key-10.4103/1673-5374.344952-47 key-10.4103/1673-5374.344952-49 key-10.4103/1673-5374.344952-4 key-10.4103/1673-5374.344952-3 key-10.4103/1673-5374.344952-2 key-10.4103/1673-5374.344952-1
References_xml	– ident: key-10.4103/1673-5374.344952-54 doi: 10.1161/STROKEAHA.117.018505 – ident: key-10.4103/1673-5374.344952-7 doi: 10.15252/emmm.201910291 – ident: key-10.4103/1673-5374.344952-27 doi: 10.1007/s40263-015-0297-0 – ident: key-10.4103/1673-5374.344952-39 doi: 10.1038/nrneurol.2012.227 – ident: key-10.4103/1673-5374.344952-22 doi: 10.2147/DDDT.S122249 – ident: key-10.4103/1673-5374.344952-70 doi: 10.1093/brain/awy338 – ident: key-10.4103/1673-5374.344952-20 doi: 10.1167/iovs.10-5392 – ident: key-10.4103/1673-5374.344952-44 doi: 10.1002/jcb.29822 – ident: key-10.4103/1673-5374.344952-11 doi: 10.3390/cells10113217 – ident: key-10.4103/1673-5374.344952-28 doi: 10.3390/cells9051108 – ident: key-10.4103/1673-5374.344952-31 doi: 10.1016/S0140-6736(17)31469-1 – ident: key-10.4103/1673-5374.344952-12 doi: 10.1007/s00401-011-0807-1 – ident: key-10.4103/1673-5374.344952-16 doi: 10.3389/fimmu.2020.00635 – ident: key-10.4103/1673-5374.344952-40 doi: 10.3390/cells9061515 – ident: key-10.4103/1673-5374.344952-48 doi: 10.4161/jkst.22925 – ident: key-10.4103/1673-5374.344952-71 doi: 10.1016/S0079-6123(08)01132-1 – ident: key-10.4103/1673-5374.344952-30 doi: 10.1016/j.neurobiolaging.2017.02.004 – ident: key-10.4103/1673-5374.344952-60 doi: 10.1038/nmeth.2089 – ident: key-10.4103/1673-5374.344952-62 doi: 10.1007/s11910-021-01110-5 – ident: key-10.4103/1673-5374.344952-67 doi: 10.1155/2016/8072156 – ident: key-10.4103/1673-5374.344952-69 doi: 10.1167/iovs.13-13262 – ident: key-10.4103/1673-5374.344952-29 doi: 10.1111/jnc.13701 – ident: key-10.4103/1673-5374.344952-41 doi: 10.1007/978-3-319-05879-5_7 – ident: key-10.4103/1673-5374.344952-58 doi: 10.3389/fneur.2020.612422 – ident: key-10.4103/1673-5374.344952-52 doi: 10.3389/fneur.2021.654850 – ident: key-10.4103/1673-5374.344952-51 doi: 10.1016/j.preteyeres.2019.100799 – ident: key-10.4103/1673-5374.344952-64 doi: 10.1002/glia.20962 – ident: key-10.4103/1673-5374.344952-65 doi: 10.1167/iovs.11-8732 – ident: key-10.4103/1673-5374.344952-25 doi: 10.1161/STROKEAHA.109.568899 – ident: key-10.4103/1673-5374.344952-42 doi: 10.3390/cells9030535 – ident: key-10.4103/1673-5374.344952-37 doi: 10.3390/pharmaceutics13010108 – ident: key-10.4103/1673-5374.344952-66 doi: 10.1186/s13578-020-00416-0 – ident: key-10.4103/1673-5374.344952-5 doi: 10.1016/j.neuron.2018.01.021 – ident: key-10.4103/1673-5374.344952-6 doi: 10.3390/cells8010024 – ident: key-10.4103/1673-5374.344952-3 doi: 10.1016/j.phrs.2016.07.042 – ident: key-10.4103/1673-5374.344952-26 doi: 10.2174/1389450116666151001112710 – ident: key-10.4103/1673-5374.344952-53 doi: 10.3390/molecules22030344 – ident: key-10.4103/1673-5374.344952-59 doi: 10.1073/pnas.1615413114 – ident: key-10.4103/1673-5374.344952-63 doi: 10.1016/j.neuron.2009.11.021 – ident: key-10.4103/1673-5374.344952-1 doi: 10.1007/s12035-020-01948-9 – ident: key-10.4103/1673-5374.344952-49 doi: 10.1016/j.jneuroim.2012.12.005 – ident: key-10.4103/1673-5374.344952-55 doi: 10.1007/s12640-019-0003-y – ident: key-10.4103/1673-5374.344952-36 doi: 10.1167/iovs.02-0398 – ident: key-10.4103/1673-5374.344952-57 doi: 10.3390/ijms21207537 – ident: key-10.4103/1673-5374.344952-72 doi: 10.1016/j.brainresbull.2020.08.013 – ident: key-10.4103/1673-5374.344952-18 – ident: key-10.4103/1673-5374.344952-21 doi: 10.1001/archneur.62.9.1345 – ident: key-10.4103/1673-5374.344952-56 doi: 10.3389/fnmol.2018.00293 – ident: key-10.4103/1673-5374.344952-2 doi: 10.7150/thno.55472 – ident: key-10.4103/1673-5374.344952-15 doi: 10.1146/annurev-pharmtox-010818-021358 – ident: key-10.4103/1673-5374.344952-24 doi: 10.1016/j.exer.2011.09.023 – ident: key-10.4103/1673-5374.344952-23 doi: 10.1016/j.exer.2006.09.013 – ident: key-10.4103/1673-5374.344952-14 doi: 10.1073/pnas.1014154108 – ident: key-10.4103/1673-5374.344952-50 doi: 10.1016/j.neuropharm.2016.11.006 – ident: key-10.4103/1673-5374.344952-19 doi: 10.1080/14656566.2018.1551363 – ident: key-10.4103/1673-5374.344952-33 doi: 10.1056/NEJMoa052643 – ident: key-10.4103/1673-5374.344952-38 doi: 10.3390/cells9081771 – ident: key-10.4103/1673-5374.344952-10 doi: 10.1038/nn.4593 – ident: key-10.4103/1673-5374.344952-68 doi: 10.1515/revneuro-2013-0003 – ident: key-10.4103/1673-5374.344952-43 doi: 10.1093/hmg/ddv218 – ident: key-10.4103/1673-5374.344952-17 doi: 10.1016/j.expneurol.2019.01.015 – ident: key-10.4103/1673-5374.344952-34 doi: 10.1016/S0140-6736(18)30475-6 – ident: key-10.4103/1673-5374.344952-73 doi: 10.1096/fj.201600751r – ident: key-10.4103/1673-5374.344952-8 doi: 10.1177/20552173211049168 – ident: key-10.4103/1673-5374.344952-9 doi: 10.1126/science.aar5551 – ident: key-10.4103/1673-5374.344952-13 doi: 10.1016/j.ymthe.2018.09.019 – ident: key-10.4103/1673-5374.344952-35 doi: 10.1016/j.bbamem.2017.03.008 – ident: key-10.4103/1673-5374.344952-47 doi: 10.1523/JNEUROSCI.2801-06.2006 – ident: key-10.4103/1673-5374.344952-61 doi: 10.1038/ncomms5859 – ident: key-10.4103/1673-5374.344952-32 doi: 10.1038/s41433-020-0809-0 – ident: key-10.4103/1673-5374.344952-45 doi: 10.1128/MCB.25.24.11113-11121.2005 – ident: key-10.4103/1673-5374.344952-46 doi: 10.1016/j.neuropharm.2018.02.023 – ident: key-10.4103/1673-5374.344952-4 doi: 10.1016/j.pneurobio.2020.101817
SSID	ssj0058923
Score	2.351636
Snippet	Sphingosine-1-phosphate receptor (S1PR) signaling regulates diverse pathophysiological processes in the central nervous system. The role of S1PR signaling in...
SourceID	doaj pubmedcentral wanfang proquest crossref wolterskluwer
SourceType	Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher
StartPage	840
SubjectTerms	Glaucoma glaucoma; intraocular pressure; neurodegeneration; neuroprotection; optic nerve injury; retinal ganglion cells; siponimod; sphingosine-1-phosphate Nervous system Optic nerve Retina
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BbtQwELVQBRIXBBREoCAjVUgcwiaxE8fqqSAqTlVFQerNchy73cI6VbPb1fbEp3fGzi4bDnDhGjuJ1zPjmdmZvEfIPjPCcQ2GZBvNUt7WVdpwZtPSyso5I1vGItmEOD6uz87kyRbVF_aERXjguHETixhr4FMg8265aCoptCsNOJrSZc7kBk_fTMh1MhXP4LKWgdgtrwRLSyZ4LFDyPGOTzbUPjEN2UIwcUsDtHwWbf7ZKPlhq77Q_h5FlhwXt_kfoZ9_ySkePyaMhnKSH8Wc8Ifesf0p2Dz2k0rMVfUdDg2f453yX_DqdXoEFz7qWItHSvKcBzHJAaoBTjw7NHbTzFOJCih84ek21b-lFaAehN9N-Aa9DGuOlXtGB5Cc-B9dxmp98zenU023iAAoR-gIUWz8j348-f_v0JR0IGFIDYVGXFhr8VytLZ4tcV42QWiP-vpMma6WGYKnCanALEQkrrM5NJRvtatmCVghbmpw9Jzu-8_YFoQ5JrsFfmlo03BQNOMGsaqSRlrMGUsKETNZSUGZAJ0eSjJ8KshSUm0K5KZSbinJLyPvNHVcRmeMvcz-iYDfzEFM7XABNU4OmqX9pWkL21mqhBkPvFZaxIWOreJaQt5thMFGsu2hvu0WYwyBqhFg1IWKkTqMFjUf89CKAfUsRqDgSsj8o3u933573l7f96lLZAjNJDqFiQg5GWqlm8aPK0c6kWzujIMFXa_V7-T-26RV5iMuJ3U17ZGd-vbCvyX1zM5_212-Cmd4B4NRAwg priority: 102 providerName: Directory of Open Access Journals
Title	Siponimod exerts neuroprotective effects on the retina and higher visual pathway through neuronal S1PR1 in experimental glaucoma
URI	http://www.nrronline.org/article.asp?issn=1673-5374;year=2023;volume=18;issue=4;spage=840;epage=848;aulast=Basavarajappa;type=0 https://www.proquest.com/docview/2720768640 https://www.proquest.com/docview/2723159545 https://d.wanfangdata.com.cn/periodical/zgsjzsyj-e202304028 https://pubmed.ncbi.nlm.nih.gov/PMC9700103 https://doaj.org/article/e0828853093d47b697af5c2385f0fc1c
Volume	18
WOSCitedRecordID	wos000903723200029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1876-7958 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0058923 issn: 1673-5374 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVEMX databaseName: Medknow Open Access Journals customDbUrl: eissn: 1876-7958 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0058923 issn: 1673-5374 databaseCode: W3E dateStart: 20110101 isFulltext: true titleUrlDefault: http://www.medknow.com/journals.asp providerName: Wolters Kluwer Health
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV3Nb9MwFLfGAIkLXwMRGJWRJiQOYUnsfFjRDhvaxGmaGEi9WS-Os7XQpGr6oe7En86znZaGAxcOXGOntpzf--p7fj9CjphKKw4oSLoA5vMyS_yCM-3HWiRVpUTJmCObSC8vs-FQXO2RTU2UrdmfzVyXCNcm2B2gvdblRDRJmR-zlOdrxMKJof_Ot5Kcu93y3IkjRi95p9V5lsMCHdL5yRm0sIQZjGE6hdz2JsKY_35kblWaKynsfKPK40xYfrjtki7PycOAHW-ffWQcg4yoZ9ds-_-ez_pnxeXDFdQV1Dc4smpMXrz9bsvid4zbxZP_fixPyePOL6anbsFnZE_Xz8nBaQ3zZrKm76mtVLUpgAPy83o0RVU0aUpqGKPmLbVdObuWE6i-aVelQpuaooNLzU3NGijUJb21dS10OWoXuJzhY17BmnZsRe53zD6uw6svIR3VdJcBgWKosUAJhRfk28X510-f_Y5Jwlfo3zV-BGiISxFXOgohKVIBYIgEKqGCUgB6fYlJa5foWrFIQ6gSUUCViRLhnepYhewl2a-bWr8itDJs3Wj4VZYWXEUFWvMgKYQSmrMCY1uPHG9wIFXXZt2wffyQGG4Z5EjzpaT5UtIhxyMftm9MXYuRv8w9M9DazjPNwe0DxITsMCG1aUuIblggWMnTIhEpVLFC3yyugkqFyiOHG2DKTmO10uTjMfRMeOCRd9th1DUmgQS1bhZ2DkP3F51uj6Q9QPc21B-pR7e2a7lILaeIR4466P9e--6mHd-167HUBrZoVqLMI3lPLuTE3Q7tnYy_czISQS038Hv9T2-_IY_MPlx91iHZn88W-i15oJbzUTsbkHvpMBvY_24GVlv8Aj3fhs4
linkProvider	Wolters Kluwer Health
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Siponimod+exerts+neuroprotective+effects+on+the+retina+and+higher+visual+pathway+through+neuronal+S1PR1+in+experimental+glaucoma&rft.jtitle=Neural+regeneration+research&rft.au=Devaraj+Basavarajappa&rft.au=Gupta%2C+Vivek&rft.au=Chitranshi%2C+Nitin&rft.au=Wall%2C+Roshana&rft.date=2023-04-01&rft.pub=Medknow+Publications+%26+Media+Pvt.+Ltd&rft.issn=1673-5374&rft.eissn=1876-7958&rft.volume=18&rft.issue=4&rft.spage=840&rft.epage=848&rft_id=info:doi/10.4103%2F1673-5374.344952&rft.externalDBID=HAS_PDF_LINK
thumbnail_s	http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgsjzsyj-e%2Fzgsjzsyj-e.jpg